Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12027691 | 0.79 | CA1 (0.39) | SMN1; SMN2CA1CA2CA7DGAT1 | |
| SCHEMBL775818 | 0.78 | SMN1; SMN2 (0.35) | DPP4SMN1; SMN2 | |
| SCHEMBL7434659 | 0.76 | SMN1; SMN2 (0.50) | DPP4SMN1; SMN2CA1CA2CA7 | |
| SCHEMBL3147895 | 0.76 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL26042723 | 0.76 | SMN1; SMN2 (0.50) | DPP4SMN1; SMN2CA1CA2CA7 | |
| SCHEMBL26958374 | 0.76 | ALDH1A1 (0.39) | DPP4SLC7A5 | |
| SCHEMBL13798757 | 0.76 | SMN1; SMN2 (0.50) | DPP4SMN1; SMN2CA1CA2CA7 | |
| SCHEMBL25404727 | 0.75 | DGAT1 (0.34) | SMN1; SMN2CA1CA2CA7DGAT1 | |
| SCHEMBL17475367 | 0.75 | DGAT1 (0.34) | SMN1; SMN2CA1CA2CA7DGAT1 | |
| SCHEMBL6633558 | 0.74 | SMN1; SMN2 (0.32) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183260-B1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS INC (US) | 2011-06-01 | — | — | EP | disclosed |
| US-7932240-B2 | Phosphadiazine HCV polymerase inhibitors IV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2183260-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| WO-2009032180-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090081158-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV | POLI, ITPA, POLR2H | DPP4 317/4885SMN1; SMN2 4370/4885CA1 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.